# ACE-CL-001 (NCT02029443)

> ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

No report yet. It can be ordered.

- Drugs tested: acalabrutinib
- Indication: chronic lymphocytic leukemia, Richter's syndrome or prolymphocytic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02029443
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Acerta Pharma BV
- Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Prolymphocytic Leukemia
- Interventions: Acalabrutinib
- Enrollment: 306
- Primary outcome: Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1
- Primary outcome: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
- Primary outcome: Number of Participants With Treatment Emergent Events of Clinical Interest (ECI)
- Primary outcome: Number of Participants With Clinically Important Laboratory Abnormalities With Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or More
- Primary outcome: Number of Participants With Clinically Abnormal Vital Signs Reported as TEAEs
- Primary outcome: Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours (AUC0-6) of Acalabrutinib
- Primary outcome: Area Under the Plasma Concentration-time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of Acalabrutinib
- Primary outcome: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Acalabrutinib
- Primary outcome: Maximum Observed Plasma Concentration (Cmax) of Acalabrutinib
- Primary outcome: Time of Maximum Plasma Concentration (Tmax) of Acalabrutinib
- Primary outcome: Terminal Elimination Half-life (t1/2) of Acalabrutinib
- Primary outcome: Terminal Elimination Rate Constant (λz) of Acalabrutinib
- Primary outcome: Apparent Oral Clearance (CL/F) of Acalabrutinib
- Primary outcome: Apparent Volume of Distribution (Vz/F) of Acalabrutinib

## Indexed commentary on ACE-CL-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ace-cl-001-nct02029443